Jiangsu Sinopep-Allsino Biopharmaceutical (SH:688076) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-08-06 00:10Group 1 - The company has received the CBPF-GMP certificate from Brazil's National Health Surveillance Agency (ANVISA), confirming compliance with international production quality management standards [1][2] - The cGMP inspection covered the company's production line for active pharmaceutical ingredients Semaglutide and Liraglutide, marking the third successful overseas compliance check after the FDA and MFDS [2][6] - This certification is expected to enhance the company's ability to promote and sell its products in international markets [2][6] Group 2 - The cGMP inspection took place from April 28 to May 2, 2025, at the company's facility located in Lianyungang Economic and Technological Development Zone [6] - The inspection concluded that the company's production practices are in accordance with cGMP regulations, which is crucial for exporting pharmaceutical products [6]